Bera Urges FDA to Take Action in Response to EpiPen Prices
EpiPens Cost Upwards of $600 for a Single Prescription
On August 25th, 2016, Congressman Ami Bera, M.D. (CA-7) called on the Food and Drug Administration (FDA) to take immediate action to make lower cost alternatives available in response to exorbitantly priced EpiPens from the drug manufacturer Mylan. Currently, EpiPens have a virtual monopoly on the market for emergency allergy attack treatment. In the letter, Congressman Bera asks the FDA to address processes that may limit competition and allow some companies to drastically increase prices. Today, Mylan announced they would offer additional coupons for EpiPens, but have not addressed the underlying cost.
“As a doctor, I know that in the case of an allergic reaction no time can be wasted and we can’t allow anything to stand in the way of immediate access to epinephrine.” said Bera. “$600 for an EpiPen is outrageous, and Mylan must be held accountable for their pricing on a life-saving drug. That’s why I’m calling on the FDA to make sure that families have other more affordable and safe options to EpiPens so that no one needs to make a choice between paying their bills or having a life-saving drug.”
Congressman Bera has previously urged the FDA to regulate the prices of life-saving drugs. He leads the push to ensure that drug companies are not able to charge excessive prices for drugs, like in the case of Martin Shkreli and Turing Pharmaceuticals.